Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by XTX Topco Ltd

XTX Topco Ltd grew its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOSFree Report) by 101.2% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 49,616 shares of the company’s stock after buying an additional 24,951 shares during the period. XTX Topco Ltd’s holdings in Atossa Therapeutics were worth $75,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Intech Investment Management LLC bought a new position in Atossa Therapeutics during the third quarter worth $29,000. SG Americas Securities LLC lifted its position in shares of Atossa Therapeutics by 254.3% in the 3rd quarter. SG Americas Securities LLC now owns 41,849 shares of the company’s stock worth $64,000 after buying an additional 30,037 shares during the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Atossa Therapeutics in the 3rd quarter valued at about $75,000. State Street Corp grew its position in shares of Atossa Therapeutics by 4.2% during the 3rd quarter. State Street Corp now owns 1,732,221 shares of the company’s stock valued at $2,633,000 after buying an additional 69,180 shares during the last quarter. Finally, Rhumbline Advisers acquired a new stake in Atossa Therapeutics during the second quarter worth about $161,000. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Therapeutics Trading Down 1.7 %

Shares of NASDAQ ATOS opened at $0.96 on Friday. Atossa Therapeutics, Inc. has a 12-month low of $0.72 and a 12-month high of $2.31. The company has a market cap of $121.23 million, a PE ratio of -4.38 and a beta of 1.21. The stock has a 50 day simple moving average of $1.31 and a 200-day simple moving average of $1.32.

Wall Street Analyst Weigh In

Several research firms have recently commented on ATOS. StockNews.com lowered Atossa Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, November 18th. Ascendiant Capital Markets upped their price objective on Atossa Therapeutics from $6.50 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 target price on shares of Atossa Therapeutics in a research note on Thursday, December 12th.

View Our Latest Stock Analysis on ATOS

About Atossa Therapeutics

(Free Report)

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.

Further Reading

Want to see what other hedge funds are holding ATOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Atossa Therapeutics, Inc. (NASDAQ:ATOSFree Report).

Institutional Ownership by Quarter for Atossa Therapeutics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.